Table 2 Clinical data of the colon cancer patients in ELISA study
From: Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis
Clinical data | Cases | Proportion | sDC-SIGNR (ng/ml) median (range) |
|---|---|---|---|
Gender | |||
 Female | 32 | 39.51% | 72.88 (33.46–245.0) |
 Male | 49 | 60.49% | 89.73 (26.81–249.3) |
Age (year) | |||
 ≧60 | 52 | 64.20% | 62.25 (29.49–249.3) |
 <60 | 29 | 35.80% | 74.76 (26.81–245.0) |
Stage | |||
 I/II | 20 | 24.69% | 58.90 (29.49–140.0) |
 III/IV | 61 | 75.31% | 70.97 (26.81–249.3) |
Type of cancer | |||
 Colon | 42 | 51.85% | 67.51 (33.83–249.3) |
 Rectal | 39 | 48.15% | 66.53 (26.81–202.2) |
Metastatic site | |||
 No | 20 | 24.69% | 58.90 (29.49–140.0) |
 Liver | 33 | 40.74% | 86.26 (33.83–202.2) |
 Other | 28 | 34.57% | 59.71 (26.81–249.3) |